Prostaglandin F2 alpha for interrupting pregnancy, managing intrauterine death and molar pregnancy and inducing labor.
Serial intramuscular injections of 250 microgram of 15 (S), 15-methyl-prostaglandin F2 alpha were given to 105 women every 1-3 hours in an attempt to induce second-trimester abortion (N = 80) or labor (N = 25), the latter because of late intrauterine death or anencephaly. The treatment was highly successful; the cumulative expulsion rates at 12 and 24 hours were 69% and 95%, respectively. There were no serious complications, and significant alterations in the mother's vital signs were uncommon. Gastrointestinal side effects are tolerable if the woman is properly premedicated and maintained on the antiemetic, antidiarrheic and analgesic treatments.
D000028:Abortion, Induced; D000030:Abortion, Missed / Q000628:therapy; D000293:Adolescent; D000328:Adult; D005260:Female; D005313:Fetal Death / Q000628:therapy; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006828:Hydatidiform Mole / Q000628:therapy; D007273:Injections, Intramuscular; D007751:Labor, Induced; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy*; D011262:Pregnancy Trimester, Second; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects; D014594:Uterine Neoplasms / Q000628:therapy
D011461:Prostaglandins F, Synthetic